Phosphonomethoxyalkyl analogs of nucleotides

Current Pharmaceutical Design

Volumn 9, Issue 31, 2003, Pages 2567-2592

  Holý, Antonín ^a  

^a INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

Author keywords

Adefovir; AIDS; Chemotherapy; Cidofovir; CMV; DNA viruses; HBV; Hepatitis B; HIV; Nucleotide analogs; Retroviruses; Tenofovir

Indexed keywords

2,6 DIAMINOPURINE; 8 AZAGUANINE; 9 (3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL)ADENINE; 9 (3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL)GUANINE; 9 [2 [PHOSPHONOMETHOXY]ETHYL] 2,6 DIAMINOPURINE; ACYCLIC NUCLEOSIDE PHOSPHONATE; ADEFOVIR; ADEFOVIR DIPIVOXIL; ALAMIFOVIR; ALKYL GROUP; ANTIVIRUS AGENT; CIDOFOVIR; CYTOSINE; CYTOSINE DERIVATIVE; DIDANOSINE; GAMMA INTERFERON; GS 7171; GS 7340; MITOMYCIN C; NELFINAVIR; NUCLEOTIDE DERIVATIVE; PRODRUG; PROTEINASE INHIBITOR; PURINE DERIVATIVE; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; DNA VIRUS; DRUG ACTIVITY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG SYNTHESIS; EYE DISEASE; HEPATITIS B; HUMAN; IMMUNOMODULATION; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIVIRAL AGENTS; DNA VIRUS INFECTIONS; DRUG DESIGN; HEPATITIS B; HUMANS; NUCLEOTIDES; PHOSPHONIC ACIDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0345138983     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612033453668     Document Type: Review

References (385)

1. Rosenberg I, Holy A. Preparation of 5′-O-phosphonylmethyl analogues of nucleoside 5′-phosphates, 5′-diphosphates and 5′-triphosphates. Collect Czech Chem Commun 1982; 47: 3447-3463.
2. Rosenberg I, Holy A. Preparation of 2′(3′)-O-phosphonylmethyl derivatives of ribonucleosides. Collect Czech Chem Commun 1983; 48: 778-789.
3. Holy A. Synthesis and biological activity of some analogues of nucleic acids components. In Phosphorus Chemistry Directed Towards Biology. W.Stec, Ed. Pergamon Press, Oxford. 1980; pp. 53-64.
4. Vesely J, Rosenberg I, Holy A. Inhibition by CTP and UTP analogues of uridine kinase from mouse leukemic cells. Collect Czech Chem Commun 1982; 47: 3464-3469.
5. Vesely J, Rosenberg I, Holy A. Donor activity of 5′-O-phosphonylmethyl analogues of ATP and GTP in the phosphorylation of uridine catalyzed by uridine kinase from mouse leukemic cells, Collect Czech Chem Commun 1983; 48: 1783-1787.
6. Horská K, Cvekl A, Rosenberg I, Holy A, Sebesta K. DNA-dependent RNA polymerase mediated formation of methylphosphonyl internucleotide linkage. Collect Czech Chem Commun 1990; 55: 2100-2109.
7. Horská K, Rosenberg I, Holy A, Sebesta K. 5′-O-Diphosphoryl-phosphonylmethylribonucleosides- A new group of DNA-dependent RNA polymerase inhibitors. Collect Czech Chem Commun 1983; 48: 1352-1357.
8. Jie L, Van Aerschot A, Balzarini J, Janssen G, Busson R, Hoogmartens J, et al. 5′-O-phosphonomethyl-2′,3′-dideoxynucleosides: synthesis and anti-HIV activity. J Med Chem 1990; 33: 2481-2487.
9. Holy A, Cihák A. Metabolism of 9-(S)-(2,3-dihydroxypropyl) adenine, all antiviral agent, in mice. Biochem Pharmacol 1981; 30: 2359-2361.
10. De Clercq E, Holy A, Rosenberg I, Sakuma T, Balzarini J, Maudgal PC. A novel selective broad-spectrum anti-DNA virus agent. Nature 1986; 323: 464-467.
11. De Clercq E, Descamps J, De Somer P, Holy A. (S)-9-(2,3-Dihydroxypropyl)adenine: an aliphatic nucleoside analog with broad-spectrum antiviral activity. Science 1978; 200: 563-564.
12. Votruba I, Hasobe M, Holy A, Borchardt RT. 2-Methylpropyl ester of 3-(adenin-9-yl)-2-hydroxypropanoic acid. Mechanism of antiviral action in vaccinia virus-infected L929 cells. Biochem Pharmacol 1990; 39: 1573-1580.
13. Votruba I, Holy A. Inhibition of S-adenosyl-L-homocysteine hydrolase by the aliphatic nucleoside analogue -9-(S)-(2,3-dihydroxypropyl)adenine. Collect Czech Chem Commun 1980; 45: 3039-3044.
14. Holy A, Rosenberg I. Synthesis of isomeric and enantiomeric O-phosphonylmethyl derivatives of 9-(2,3-dihydroxypropyl)adenine. Collect Czech Chem Commun 1987; 52: 2775-2791.
15. Holy A, Rosenberg I. Synthesis of 9-(2-phosphonylmethoxyethyl) adenine and related compounds. Collect Czech Chem Commun 1987; 52: 2801-2809.
16. Pauwels R, Balzarini J, Schols D, Baba M, Desmyter J, Rosenberg I, et al. Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrob Agents Chemother 1988; 32: 1025-1030.
17. Balzarini J, Naesens L, Herdewijn P, Rosenberg I, Holy A, Pauwels R, et al. Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent. Proc Natl Acad Sci USA 1989; 86: 332-336.
18. Rosenberg I, Holy A, Masojídková M. Phosphonylmethoxyalkyl and phosphonylalkyl derivatives of adenine. Collect Czech Chem Commun 1988; 53: 2753-2777.
19. Holy A, De Clereq E, Votruba I. In Nucleotide Analogues as Antiviral Agents, Martin JC, Ed, American Chemical Society, ACS Symposium Series #401, Washington. DC. 1989; pp. 51-71.
20. De Clercq E, Sakuma T, Baba M, Pauwels R, Balzarini J, Rosenberg I, et al. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res 1987; 8: 261-272.
21. Snoeck R, Sakuma T, De Clercq E, Rosenberg I, Holy A. (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother 1988; 32: 1839-1844.
22. Holy A, Ivanova GS. Aliphatic analogues of nucleotides: synthesis and affinity towards nucleases. Nucleic Acids Res 1974; 1: 19-34.
23. Holy A. Synthesis of N-(2,3-dihydroxypropyl) derivatives of heterocyclic bases. Collect Czech Chem Commun 1978; 43: 2054-2061.
24. Holy A. Preparation of new mono- and disubstituted hydroxy- and aminoalkyl derivatives of heterocyclic bases. Collect Czech Chem Commun 1978; 43: 3444-3465.
25. Holy A. Synthesis of some 2,3-dihydroxypropyl derivatives of purine bases. Collect Czech Chem Commun 1978; 43: 3103-3117.
26. Holy A. Synthesis of racemic and optically active erythro- and threo- 9-(2,3,4-trihydroxybutyl)adenines and related compounds. Collect Czech Chem Commun 1979; 44: 593-611.
27. Holy A, Votruba I, De Clercq E. Structure-activity studies open-chain analogues of nucleosides: inhibition of S-adenosyl-L-homocysteine hydrolase and antiviral activity. Collect Czechoslov Chem Commun 1985; 50: 245-261.
28. Yu RH, Schultze LM, Rohloff JC, Dudzinski PW, Kelly DE. Process optimization in the synthesis of 9-[2-(Diethylphosphonomethoxy)ethyl]adenine: Replacement of sodium hydride with sodium tert-butoxide as the base for oxygen alkylation. Org Process Res Dev 1999; 3: 53-55.
29. Schultze LM, Chapman HH, Dubree NJP, Jones RJ, Kent KM, Lee TT, et al. Practical synthesis of the anti-HIV drug, PMPA. Tetrahedron Lett 1998; 39: 1853-1856.
30. Holy A, Rosenberg I. Stereospecific syntheses of 9-(S)-(3-hydroxy-2-phosphonylmethoxypropyl)adenine (HPMPA). Nucleic Acids Symp Ser, 1987; 18: 33-36.
31. Webb RR II, Martin JC. A convenient synthesis of S-HPMPA. Tetrahedron Lett 1987; 28: 4963-4964.
32. Webb RR II, Wos JA, Bronson JJ, Martin JC. Synthesis of (S)-N-(3-hydroxy-2-phosphonylmethoxy)propylcytosine, (S)-HPMPC. Tetrahedron Lett 1988; 29: 5475-5478.
33. Brodfuehrer PR, Howell HG, Sapino C, Vemishetti P. A practical synthesis of (S)-HPMPC. Tetrahedron Lett 1994; 35: 3243-3246.
34. Holy A. Syntheses of Enantiomeric N-(3-Hydroxy-2-phosphonomethoxypropyl) Derivatives of Purine and Pyrimidine Bases. Collect Czech Chem Commun 1993; 58: 649-674.
35. Dvoráková H, Holy A, Alexander P. Synthesis and Biological Effects of 9-(3-hydroxy-2-phosphonomethoxypropyl) Derivatives of Deazapurine Bases. Collect Czech Chem Commun 1993; 58: 1403-1418.
36. Holy A, Masojídková M. Synthesis of enantiomeric N-(2-phosphonomethoxypropyl) derivatives of purine and pyrimidine bases. 1. The stepwise approach. Collect Czech Chem Commun 1995; 60: 1196-1212.
37. Jindrich J, Holy A, Dvoráková H. Synthesis of N-(3-Fluoro-2-phosphonomethoxypropyl) (FPMP) Derivatives of Heterocyclic Bases. Collect Czech Chem Commun 1993; 58: 1645-1667.
38. Dvoráková H, Masojídková M, Holy A, Balzarini J, Andrei G, Snoeck R, et al. Synthesis of 2′-aminomethyl derivatives of N-(2-phosphonomethoxy)ethyl) nucleotide analogues as potential antiviral agents. J Med Chem 1996; 39: 3263-3268.
39. Dvoráková H, Holy A, Rosenberg I. Synthesis of some 2′-C-alkyl derivatives of 9-(2-phosphonomethoxyethyl)adenine and related compounds. Collect Czech Chem Commun 1994; 59: 2069-2094.
40. Kim CU, Misco PF, Luh BY, Hitchcock MJ, Ghazzouli I, Martin JC. A new class of acyclic phosphonate nucleotide analogues: phosphonate isosteres of acyclovir and ganciclovir monosphates as antiviral agents. J Med Chem 1991; 34: 2286-2294.
41. Kim CU, Luh BY, Martin JC. Synthesis and antiviral activity of (S)-9-[4-hydroxy-3-(phosphonomethoxy)butyl]guanine. J Med Chem 1990; 33: 1797-1800.
42. Holy A, Rosenberg I, Dvoráková H. Synthesis of (3-hydroxy-2-phosphonylmethoxypropyl) derivatives of heterocyclic bases. Collect Czech Chem Commun 1989; 54: 2470-2501.
43. Holy A, Günter J, Dvoráková H, Masojídková M, Andrei G, Snoeck R, et al. Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base. J Med Chem 1999; 42: 2064-2086.
44. Holy A, Rosenberg I, Dvoráková H. Synthesis of N-(2-phosphonylmethoxyethyl) derivatives of heterocyclic bases. Collect Czech Chem Commun 1989; 54: 2190-2210.
45. Hocková D, Masojídková M, Budesínsky M, Holy A. Acyclic nucleoside and nucleotide analogs derived from 2-azaadenine. Collect Czech Chem Commun 1995; 60: 224-236.
46. Holy A, Dvoráková H, Jindrich J, Masojídková M, Budesínsky M, Balzarini J, et al. Acyclic nucleotide analogs derived from 8-azapurines: synthesis and antiviral activity. J Med Chem 1996; 39: 4073-4088.
47. Dvoáková H, Holy A. Synthesis and Biological Effects of N-(2-Phosphonomethoxyethyl) Derivatives of Deazapurine Bases. Collect Czech Chem Commun 1993; 58: 1419-1429.
48. Hocek M, Masojídková M, Holy A. Synthesis of acyclic nucleotide analogues derived from 2-(aminomethyl)adenine and 2-(aminomethyl)hypoxanthine. Collect Czech Chem Commun 1995; 60: 875-882.
49. Hocek M, Masojídková M, Holy A, Andrei G, Snoeck R, Balzarini J, et al. Synthesis and antiviral activity of acyclic nucleotide analogues derived from 6-(aminomethyl)purines and purine-6-carboxamidines. Collect Czech Chem Commun 1996; 61: 1525-1537.
50. Bronson JJ, Ghazzouli I, Hitchcock MJ, Webb RR, Martin JC. Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. J Med Chem 1989; 32: 1457-1463.
51. Chen W, Flavin MT, Filler R, Xu ZQ. An improved synthesis of 9-2-(diethoxyphosphonomethoxy)ethyl]adenine and its analogues with other purine bases utilizing the Mitsunobu reaction. Nucleos Nucleot 1996; 15: 1771-1778.
52. Holy A, Budesínsky M, Podlaha J, Císarová I. Synthesis of N1-2-(phosphonomethoxy)ethyl] derivatives of 2,4-diaminopyrimidine and related acyclic nucleotide analogs. Collect Czech Chem Commun 1999; 64: 242-256.
53. Holy A, Dvoráková H, Masojídková M. Synthesis of enantiomeric N-(2-phosphonomethoxypropyl) derivatives of heterocyclic bases. 2. Synthon approach. Collect Czech Chem Commun 1995; 60: 1390-1409.
54. 14]HPM PC). J Label Comp Radiopharm 1991; 29: 1217-1221.
55. Ho HT, Woods KL, Bronson JJ, De Boeck H, Martin JC, Hitchcock MJ. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Mol Pharmacol 1992; 41: 197-202.
56. Alexander P, Holy A. General method for the preparation of N-(3-hydroxy-2-phosphonomethoxypropyl) derivatives of heterocyclic bases. Collect Czech Chem Commun 1993; 58: 1151-1163.
57. Holy A, Dvoráková H. Acyclic nucleotide analogues and related compounds. Nucleos Nucleot 1995; 14: 695-702.
58. Holy A, Rosenberg I, Dvoráková H. Synthesis of N-[2-(2-Phosphonylethoxy)ethyl] Derivatives of Heterocyclic Bases. Collect Czech Chem Commun 1990; 55: 809-818.
59. Yu KL, Bronson JJ, Yang H, Patick A, Alam, M, Brankovan V, et al. Synthesis and antiviral activity of 2′-substituted 9-[2-phosphonomethoxy)ethyl]guanine analogues. J Med Chem 1993; 36: 2726-2738.
60. Yu KL, Bronson JJ, Yang H, Patick A, Alam M, Brankovan V, et al. Synthesis and antiviral activity of methyl derivatives of 9-[2-phosphonomethoxy)ethyl]guanine. J Med Chem 1992; 35: 2958-2969.
61. Villemin D, Thibault-Starzyk F. Synthesis of a new sulfur analog of PMEA. Synth Commun 1993; 23: 1053-1059.
62. Casara PJ, Altenburger J-M, Taylor DL, Tyms AS, Kenny M, Nave JF. Synthesis and antiviral activity of rigid acyclonucleotide analogs. Bioorg Med Chem Letter 1995; 5: 1275-1280.
63. Alexander P, Holy A, Masojídková M. Synthesis of 9-(2-Phosphinomethoxyethyl)adenine and related compounds. Collect Czech Chem Commun 1994; 59: 1870-1878.
64. Franchetti P, Abu-Sheikha G, Cappellacci L, Messina L, Grifantini M, Loi AG, et al. 8-Aza-analogues of PMEA and PMEG: Synthesis and in vitro anti- HIV activity. Nucleos Nucleot 1994; 13: 1707-1719.
65. Franchetti P, Abu-Sheikha G, Cappellacci L, Grifantini M, Demontis A, Piras G, et al. Synthesis and antiviral activity of 8-aza analogs of chiral [2-(phosphonomethoxy)propyl]guanines. J Med Chem 1995; 38: 4007-4013.
66. Franchetti P, Abu-Sheikha G, Perlini P, Farhat F, Grifantini M, Perra G, et al. Synthesis of unsaturated analogues of 9-[2-(phosphonomethoxy)propyl]guanine as antiviral agents. Nucleos Nucleot 1997; 16: 1921-1932.
67. Holy A. Synthesis of 3-amino- and 3-azidoanalogs of 9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine (HPMPA). Collect Czech Chem Commun 1989; 54: 446-454.
68. Hocková D, Masojídková M, Holy A. "Abbreviated" NAD(+) analogues containing a phosphonate function. Collect Czech Chem Commun 1996; 61: 1538-1548.
69. Janeba Z, Holy A. Intramolecular cyclization of some (S)-9-(3-hydroxy-2-phosphonomethoxypropyl)adenine derivatives Collect Czech Chem Commun 2001; 65: 1126-1144.
70. Holy A, Snoeck R, Balzarini J, Andrei G, De Clercq E. Antiviral activity of 2-phosphonomethoxyalkyl derivatives of N6-substituted 6-aminopurines. Antiviral Res 1995; 26: A231. International Conference on Antiviral Research, Santa Fe, April 1995.
71. Holy A, Zidek Z, Votruba I. Inhibition of murine lymphocyte proliferation by N-6-substituted acyclic purine nucleoside phosphonates. Collect Czech Chem Commun 1996; 61: S182 - S187. Xth Symposium on the Chemistry of Nucleic Acid Components, Trest Castle, Czech Republic, September 1-7, 1996.
72. Dvoráková H, Dvorák D, Holy A. Synthesis of acyclic nucleotide analogues derived from 6-(sec- or tert-alkyl)purines via coupling of 6-chloropurine derivatives with organocuprates. Collect Czech Chem Commun 1998; 63: 2065-2074.
73. Hocek M, Holy A. Perfluoroalkylation of 6-iodopurines by trimethyl(perfluoroalkyl)silanes. Synthesis of 6-(perfluoroalkyl) purine bases, nucleosides and acyclic nucleotide analogues. Collect Czech Chem Commun 1999; 64: 229-241.
74. Hocek M, Masojídková M, HolyA. Synthesis of acyclic nucleotide analogues derived from 6- hetarylpurines via cross-coupling reactions of 9-[2-(diethoxyphosphonylmethoxy)ethyl]-6-iodopurine with hetaryl organometallic reagents. Collect Czech Chem Commun 1997; 62: 136-146.
75. Hocek M, Masojídková M, Holy A. Synthesis of acyclic nucleotide analogues derived from N-substituted 6-(1-aminoethyl)purines via 6-acetylpurine derivatives. Tetrahedron 1997; 53: 2291-2302.
76. Cesnek M, Hocek M, Holy A. Synthesis of acyclic nucleotide analogues derived from 2-amino-6-C-substituted purines via cross-coupling reactions of 2-amino-9-[2-(diisopropoxyphosphorylmethoxy)ethyl]-6-halopurines with diverse organometallic reagents. Collect Czech Chem Commun 2000; 65: 1357-1373.
77. Cesnek M, Hocek M, Holy A. Cross-coupling reactions of 2-amino-6-halopurine derivatives with organometallic reagents leading to 6-alkylated purine acyclic nucleotide analogues. Collection Symposium Series 1999; 2, 255 - 256. XI. Symposium on Chemistry of Nucleic Acid Components, Spindleruv Mlyn. September 4-9, 1999.
78. Russell JW, Marrero D, Whiterock VJ, Klunk LJ, Starrett JE. Determination of 9-[(2-phosphonylmethoxy)ethyl]adenine in rat urine by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1991; 572: 321-326.
79. Naesens L, Balzarini J, De Clercq E. Acyclic adenine nucleoside phosphonates in plasma determined by high-performance liquid chromatography with fluorescence detection. Clin Chem 1992; 38: 480-485.
80. Sparidans RW, Veldkamp A, Hoetelmans RMW, Beijnen JH. Improved and simplified liquid chromatographic assay for adefovir, a novel antiviral drug, in human plasma using derivatization with chloroacetaldehyde. J Chromatogr B 1999; 736: 115-121.
81. Rosenberg I, Holy A. Synthesis of potential prodrugs and metabolites of 9-(S)-(3-hydroxy-2-phosphonylmethoxypropyl) adenine. Collect Czech Chem Commun 1987; 52: 2792-2800.
82. Bischofberger N, Hitchcock MJ, Chen MS, Barkhimer DB, Cundy KC, Kent KM, et al. 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl] cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo. Antimicrob Agents Chemother 1994; 38: 2387-2391.
83. Mendel DB, Cihlar T, Moon K, Chen MS. Conversion of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine to cidofovir by an intracellular cyclic CMP phosphodiesterase. Antimicrob Agents Chemother 1997; 41: 641-646.
84. Oliyai R, Lee WA, Visor GC, Yuan LC. Enhanced chemical stability of the intracellular prodrug, 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine, relative to its parent compound, cidofovir. Int J Pharm 1999; 179: 257-265.
85. Alexander P, Holy A, Masojídková M. Preparation of 9-(2-Phosphonomethoxyethyl)adenine Esters as Potential Prodrugs. Collect Czech Chem Commun 1994; 59: 1853-1869.
86. Holy A. Simple method for cleavage of phosphonic acid diesters to monoesters, Synthesis-Stuttgart 1998; 381-385.
87. Starrett JE Jr, Tortolani DR, Russell J, Hitchcock MJ, Whiterock V, Martin JC, et al. Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-phosphonomethoxy)ethyl]adenine (PMEA). J Med Chem 1994; 37: 1857-1864.
88. Starrett JE Jr, Tortolani DR, Hitchcock MJ, Martin JC, Mansuri MM. Synthesis and in vitro evaluation of a phosphonate prodrug: bis(pivaloyloxymethyl) 9-(2-phosphonylmethoxymethyl)adenine. Antiviral Res 1992; 19: 267-273.
89. Arimilli MN, Dougherty J, Cundy KC, Bischofberger N. Orally bioavailable acyclic nucleoside phosphonate prodrugs: adefovir dipivoxil and bis(POC)PMPA. Adv Antiviral Drug Res 1999; 3: 69-91.
90. Arimilli MN, Kim CU, Dougherty J, Mulato A, Oliyai R, Shaw JP, et al. Synthesis, in vitro biological evaluation and oral bioavailability of 9-[2-(phosphonomethoxy) propyl]adenine (PMPA) prodrugs. Antivir Chem Chemother 1997; 8: 557-564.
91. Benzaria S, Pelicano H, Johnson R, Maury G, Imbach JL, Aubertin AM, et al. Synthesis, in vitro antiviral evaluation, and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability. J Med Chem 1996; 39: 4958-4965.
92. Ballatore C, McGuigan C, De Clercq E, Balzarini J. Synthesis and evaluation of novel amidate prodrugs of PMEA and PMPA. Bioorg Medicinal Chem Letter 2001; 11: 1053-1056.
93. Rossi L, Serafini S, Cappellacci L, Balestra E, Brandi G, Schiavano GF, et al. Erythrocyte-mediated delivery of a new homodinucleotide active against human immunodeficiency virus and herpes simplex virus. J Antimicrob Chemother 2001; 47: 819-827.
94. Düzgünes N, Pretzer F, Simoes S, Slepushkin V, Konopka K, Flasher D, et al. Liposome-mediated delivery of antiviral agents to human immunodeficiency virus-infected cells. Mol Membr Biol 1999; 16: 111-118.
95. de Vrueh RLA, Rump ET, Biessen EAL, Balzarini J, van Berkel TJC, Bijsterbosch MK. Lipophilic derivatization of the anti-viral drug 9-(2-phosphonylmethoxyethyl)adenine and its incorporation into a lactosylated lipid carrier to improve its liver uptake. Nucleos Nucleot 1997; 16: 1279-1282.
96. de Vrueh RL, Rump ET, Sliedregt LA, Biessen EA, van Berkel TJ, Bijsterbosch MK. Synthesis of a lipophilic prodrug of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) and its incorporation into a hepatocyte-specific lipidic carrier. Pharm Res 1999; 16: 1179-1185.
97. de Vrueh RL, Rump ET, van De BE, van Veghel R, Balzarini J, Biessen EA, et al. Carrier-mediated delivery of 9-(2-phosphonylmethoxyethyl)adenine to parenchymal liver cells: a novel therapeutic approach for hepatitis B, Antimicrob Agents Chemother 2000; 44: 477-483;
98. Bijsterbosch MK, Ying CX, deVrueh RLA, DcClercq E, Biessen EAL, Neyts J, et al. Carrier-mediated delivery improves the efficacy of 9-(2-phosphonylmethoxyethyl)adenine against hepatitis B virus. Mol Pharmacol 2001; 60: 521-527.
99. Biessen EAL, Valentijn ARPM, DeVrueh RLA, Van deBilt E, Sliedregt LAJM, Prince P, et al. Novel hepatotrophic prodrugs of the antiviral nucleoside 9-(2-phosphonylmethoxyethyl)adenine with improved pharmacokinetics and antiviral activity. FASEB J 2000; 14: 1784-1792.
100. Midoux P, Negre E, Roche AC, Mayer R, Monsigny M, Balzarini J, et al. Drug targeting: anti-HSV-1 activity of mannosylated polymer-bound 9-(2-phosphonylmethoxyethyl)adenine. Biochem Biophys Res Commun 1990; 167: 1044-1049.
101. Besen G, Flores-Aguilar M, Assil KK, Kuppermann BD, Gangan P, Pursley M, et al. Long-term therapy for herpes retinitis in an animal model with high-concentrated liposome-encapsulated HPMPC. Arch Ophthalmol 1995; 113: 661-668;
102. Kuppermann BD, Assil KK, Vuong C, Besen G, Wiley CA, De Clercq E, et al. Liposome-encapsulated (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cyto-sine for long-acting therapy of viral retinitis. J Infect Dis 1996; 173: 18-23.
103. Santoyo S, de Jalon E, Ygartua P, Renedo M, Blanco P, Eto, M. Optimization of topical cidofovir penetration using microparticles. Int J Pharm 2002; 242: 107.
104. Otmar M, Votruba I, Holy A. An alternative synthesis of HPMPC and HPMPA diphosphoryl derivatives, Collection Symposium Series 1999, 2, 252-254. XI.Symposium on Chemistry of Nucleic Acid Components, Spindleruv Mlyn. September 4-9, 1999.
105. Otmar M, Masojídková M, Votruba I, Holy A. An alternative synthesis of HPMPC and HPMPA diphosphoryl derivatives. Collect Czech Chem Commun 2001; 66: 500-506.
106. Palu G, Stefanelli S, Rassu M, Parolin C, Balzarini J, De Clercq E. Cellular uptake of phosphonylmethoxyalkypurine derivatives. Antiviral Res 1991; 16: 115-119.
107. Cihlár T, Rosenberg I, Votruba I, Holy A. Transport of 9-(2-phosphonomethoxyethyl)adenine across plasma membrane of HeLa S3 cells is protein mediated, Antimicrob Agents Chemother 1995; 39: 117-124.
108. Olsanská L, Cihlár T, Votruba I, Holy A. Transport of adefovir (PMEA) in human T-lymphoblastoid cells. Collect Czech Chem Commun 1997; 62: 821-828.
109. Robbins BL, Connelly MC, Marshall DR, Srinivas RV, Fridland A. A human T lymphoid cell variant resistant to the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl)adenine shows a unique combination of a phosphorylation defect and increased efflux of the agent. Mol Pharmacol 1995; 47: 391-397.
110. Balzarini J, Hatse S, Naesens L, De Clercq E. Selection and characterisation of murine leukaemia L1210 cells with high-level resistance to the cytostatic activity of the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl) adenine (PMEA). Biochim Biophys Acta 19981402: 29-38.
111. Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, et al. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 1999; 5: 1048-1051.
112. Wijnholds J, Mol CAAM, van Deemter L, deHaas M, Scheffer GL, Baas F, et al. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci USA 2000; 97: 7476-7481.
113. Mulato AS, Ho ES, Cihlar T. Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther 2000; 295: 10-15.
114. Connelly MC, Robbins BL, Fridland A. Mechanism of uptake of the phosphonateanalog(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine (HPMPC) in Vero cells. Biochem Pharmacol 1993; 46: 1053-1057.
115. Ho ES, Lin DC, Mendel DB, Cihlar T. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol 2000; 11: 383-393.
116. Annaert P, Kinget R, Naesens L, De Clercq E, Augustijins P. Transport, uptake, and metabolism of the bis(pivaloyloxymethyl)ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine in an in vitro cell culture system of the intestinal mucosa (Caco-2). Pharm Res 1997; 14: 492-496.
117. Annaert P, Vangelder J, Naesens L, De Clercq E, Vandenmooter G, Kinget R, et al. Carrier mechanisms involved in the transepithelial transport of bis(POM)-PMEA and its metabolites across Caco-2 monolayers. Pharm Res 1998; 15: 1168-1173.
118. Naesens L, Bischofberger N, Augustijns P, Annaert P, Vandenmooter G, Arimilli MN, et al. Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxy) 9-(2-phosphonylmethoxypropyl)adenine in mice. Antimicrob Agents Chemother 1998; 42: 1568-1573.
119. Merta A, Votruba I, Jindrich J, Holy A, Cihlár T, Rosenberg I, et al. Phosphorylation of 9-(2-phosphonome-thoxyethyl)adenine and 9-(S)-(3-hydroxy-2-phosphonomethoxy-propyl)adenine by AMP(dAMP) kinase from L1210 cells. Biochem Pharmacol 1992; 44: 2067-2077.
120. Merta A, Vesely J, Votruba I, Rosenberg I, Holy A. Phosphorylation of acyclic nucleotide analogs HPMA and PMEA in L1210 mouse leukemia cell extracts. Neoplasma 1990; 37: 111-120.
121. Pisarev VM, Lee SH, Connelly MC, Fridland A. Intracellular metabolism and action of acyclic nucleoside phosphonates on DNA replication. Mol Pharmacol 1997; 52: 63-68.
122. Krejcová R, Horská K, Votruba I, Holy A. Phosphorylation of purine (phosphonomethoxy)alkyl derivatives by mitochondrial AMP kinase (AK2 type) from L1210 cells. Collect Czech Chem Commun 2000; 65: 1653-1668.
123. Krejcová R, Horská K, Votruba I, Holy A. Isoenzymes of GMP kinase from L1210 cells: isolation and characterization. Collect Czech Chem Commun 1999; 64: 559-570.
124. Krejcová R, Horská K, Votruba I, Holy A. Phosphorylation of phosphonomethoxyalkylguanines by GMP- kinase isoenzymes. Collect Czech Chem Commun 1996; 61: S134-S136.
125. Krejcová R, Horská K, Votruba I, Holy A. Interaction of guanine phosphonomethoxyalkyl derivatives with GMP kinase isoenzymes. Biochem Pharmacol 2000; 60: 1907-1913.
126. Robbins BL, Greenhaw J, Connelly MC, Fridland A. Metabolic pathways for activation of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine in human lymphoid cells. Antimicrob Agents Chemother 1995; 39: 2304-2308.
127. Cihlar T, Chen MS. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Mol Pharmacol 1996; 50: 1502-1510.
128. Cundy KC, Li ZH, Hitchcock MJ, Lee WA. Pharmacokinetics of cidofovir in monkeys. Evidence for a prolonged elimination phase representing phosphorylated drug. Drug Metabol Disp 1996; 24: 738-744.
129. Eisenberg EJ, Lynch GR, Bidgood AM, Krishnamurty K, Cundy KC. Isolation and identification of a metabolite of cidofovir from rat kidney. J Pharm Biomed Anal 1998; 16: 1349-1356.
130. Cihlár T, Votruba I, Horská K, Liboska R, Rosenberg I, Holy A. Metabolism of 1-(S)-(3-hydroxy-2-phosphonomethoxypropyl) cytosine (HPMPC) in human embryonic lung cells. Collect Czech Chem Commun 1992; 57: 661-672.
131. Aduma P, Connelly MC, Srinivas RV, Fridland A. Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates. Mol Pharmacol 1995; 47: 816-822.
132. Votruba I, Bernaerts R, Sakuma T, De Clercq E, Merta A, Rosenberg I, et al. Intracellular phosphorylation of broad-spectrum anti-DNA virus agent (S)-9-(3-hydroxy-2-phosphonyl-methoxypropyl)adenine and inhibition of viral DNA synthesis. Mol Pharmacol 1987; 32: 524-529.
133. Balzarini J, De Clercq E. 5-Phosphoribosyl 1-pyrophosphate synthetase converts the acyclic nucleoside phosphonates 9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and 9-(2-phosphonylmethoxyethyl)adenine directly to their antivirally active diphosphate derivatives. J Biol Chem 1991; 266: 8686-8689.
134. Merta A, Votruba I, Rosenberg I, Otmar M, Hrebabecky H, Bernaerts R, et al. Inhibition of herpes simplex virus DNA polymerase by diphosphates of acyclic phosphonylmethoxyalkyl nucleotide analogues. Antiviral Res 1990; 13: 209-218.
135. Votruba I, Trávnícek M, Rosenberg I, Otmar M, Merta A, Hrebabecky H, et al. Inhibition of avian myeloblastosis virus reverse transcriptase by diphosphates of acyclic phosphonylmethyl nucleotide analogues. Antiviral Res 1990; 13: 287-293.
136. Balzarini J, Hao Z, Herdewijn, P, Johns DG, De Clercq E. Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. Proc Natl Acad Sci USA 1991; 88: 1499-1503.
137. Kramata P, Cerny J, Birkus G, Votruba I, Otová B, Holy A. DNA-polymerases alpha, delta and epsilon from T-cell spontaneous lymphoblastic leukemia of Sprague-Dawley inbred rat: Isolation and characterization. Collect Czech Chem Commun 1995; 60: 1555-1572.
138. Kramata P, Votruba I, Otová B, Holy A. Different inhibitory potencies of acyclic phosphonomethoxyalkyl nucleotide analogs toward DNA polymerases alpha, delta and epsilon. Mol Pharmacol 1996; 49: 1005-1011.
139. Cihlar T, Chen MS. Incorporation of selected nucleoside phosphonates and anti-human immunodeficiency virus nucleotide analogues into DNA by human DNA polymerases alpha, beta and gamma. Antivir Chem Chemother 1997; 8: 187-195.
140. Birkus G, Kramata P, Votruba I, Otová B, Otmar M, Holy A. Nonproteolyzed form of DNA-polymerase epsilon from T-cell spontaneous lymphoma of Sprague-Dawley inbred rat: Isolation and characterization. Collect Czech Chem Commun 1998; 63: 723-731.
141. Birkus G, Votruba I, Holy A, Otová B. 9-[2-(Phosphonomethoxy) ethyl]adenine diphosphate (PMEApp) as a substrate toward replicative DNA polymerases alpha, delta, epsilon, and epsilon*. Biochem Pharmacol 1999; 58: 487-492.
142. Kramata P, Downey KM, Paborsky LR. Incorporation and excision of 9-(2-phosphonylmethoxyethyl)guanine (PMEG) by DNA polymerase delta and epsilon in vitro. J Biol Chem 1998; 273: 21966-21971.
143. Neyts J, Stals F, Bruggeman C, De Clercq E. Activity of the anti-HIV agent 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine against cytomegalovirus in vitro and in vivo. Eur J Clin Microbiol Infect Dis 1993; 12: 437-446.
144. Xiong X, Smith JL, Kim C, Huang ES, Chen MS. Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase. Biochem Pharmacol 1996; 51: 1563-1567.
145. Vonka V, Anisimova E, Cerny J, Holy A, Rosenberg I, Votruba I. Properties of a 9-(2-phosphonylmethoxyethyl)adenine (PMEA)-resistant herpes simplex virus type 1 virus mutant. Antiviral Res 1990; 14: 117-121.
146. Cerny J, Votruba I, Vonka V, Rosenberg I, Otmar M, Holy A. Phosphonylmethyl ethers of acyclic nucleoside analogues: inhibitors of HSV-1 induced ribonucleotide reductase. Antiviral Res 1990; 13: 253-264.
147. Kramata P, Downey KM. 9-(2-phosphonylmethoxyethyl) derivatives of purine nucleotide analogs: A comparison of their metabolism and interaction with cellular DNA synthesis. Mol Pharmacol 1999; 56: 1262-1270.
148. Hatse S, De Clercq E, Balzarini J. Impact of 9-(2-phosphonylmethoxyethyl)adenine on (deoxy)ribonucleotide metabolism and nucleic acid synthesis in tumor cells. FEBS Lett 1999; 445: 92-97.
149. Balzarini J, Holy A, Jindrich J, Naesens L, Snoeck R, Schols D, et al. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine, Antimicrob Agents Chemother 1993; 37: 332-338.
150. Reymen D, Naesens L, Balzarini J, Holy A, Dvoráková H, De Clercq E. Antiviral activity of selected acyclic nucleoside analogues against human herpesvirus 6. Antiviral Res 1995; 28: 343-357.
151. Manichanh C, Grenot P, Gautheret-Dejean A, Debré P, Huraux JM, Agut H. Susceptibility of human herpesvirus 6 to antiviral compounds by flow cytometry analysis. Cytometry 2000; 40: 135-140.
152. Yokota T, Konno K, Chonan E, Mochizuki S, Kojima K, Shigeta S, et al. Comparative activities of several nucleoside analogs against duck hepatitis B virus in vitro. Antimicrob Agents Chemother 1990; 34: 1326-1330.
153. Yokota T, Mochizuki S, Konno K, Mori S, Shigeta S, De Clercq E. Inhibitory effects of selected antiviral compounds on human hepatitis B virus DNA synthesis. Antimicrob Agents Chemother 1991; 35: 394-397.
154. Heijtink RA, Kruining J, de Wilde GA, Balzarini J, De Clercq E, Schalm SW. Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture. Antimicrob Agents Chemother 1994; 38: 2180-2182.
155. Pauwels R, De Clercq E. Development of vaginal microbicides for the prevention of heterosexual transmission of HIV. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11: 211-221.
156. Pauwels R, Schols D. Development of new potent and selective agents against HIV (human immunodeficiency virus). Verh K Acad Geneeskd Belg 1991; 53: 629-655.
157. Hartmann K, Balzarini J, Higgins J, De Clercq E, Pedersen NC. In vitro Activity of Acyclic Nucleoside Phosphonate Derivatives Against Feline Immunodeficiency Virus in Crandell Feline Kidney Cells and Feline Peripheral Blood Lymphocytes. Antivir Chem Chemother 1994; 5: 13-19.
158. Thormar H, Balzarini J, Holy A, Jindrich J, Rosenberg I, Debyser Z, et al. Inhibition of visna virus replication by 2′,3′-dideoxynucleosides and acyclic nucleoside phosphonate analogs. Antimicrob Agents Chemother 1993; 37: 2540-2544.
159. Thormar H, Georgsson G, Palsson PA, Balzarini J, Naesens L, Torsteinsdotti S, et al. Inhibitory effect of 9-(2-phosphonylmethoxyethyl)adenine on visna virus infection in lambs: a model for in vivo testing of candidate anti-human immunodeficiency virus drugs. Proc Natl Acad Sci USA 1995; 92: 3283-3287.
160. Barnard DL, Bischofberger N, Kim CU, Huffman JH, Sidwell RW, Dougherty JR, et al. Acyclic phosphonomethylether nucleoside inhibitors of respiratory viruses. Antivir Chem Chemother 1997; 8: 223-233.
161. Balzarini J, Holy A, Jindrich J, Dvoráková H, Hao Z, Snoeck R, et al. 9-[(2RS)-3-fluoro-2-phosphonylmethoxypropyl] derivatives of purines: a class of highly selective antiretroviral agents in vitro and in vivo. Proc Natl Acad Sci USA 1991; 88: 4961-4965.
162. Hartmann K, Kuffer M, Balzarini J, Naesens L, Goldberg M, Erfle V, et al. Efficacy of the acyclic nucleoside phosphonates (S)-9-(3-fluoro-2-phosphonylmethoxypropyl)adenine (FPMPA) and 9-(2-phosphonylmethoxyethyl)adeninne (PMEA) against feline immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17: 120-128.
163. Balzarini J, Aquaro S, Perno CF, Witvrouw M, Holy A, De Clercq E. Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems. Biochem Biophys Res Commun 1996; 219: 337-341.
164. Kim CU, Luh BY, Misco PF, Bronson JJ, Hitchcock MJ, Ghazzouli I, et al. Acyclic purine phosphonate analogues as antiviral agents. Synthesis and structure-activity relationships J Med Chem 1990; 33: 1207-1213.
165. Perkins RM, Duckworth DM, Elphick L, Duckworth DM, Harnden MR, Kenig MD, et al. Antiviral activity of 9-[2-(phosphonomethoxy)ethoxy]purines against HIV, FIV and Visna virus. Antiviral Res 1992; 17 Suppl. 1, 59.
166. Balzarini J, Kruining J, Heijtink R, De Clercq E. Comparative antiretrovirus and anti-hepadnavirus activity of three different classes of nucleoside phophonate derivatives. Antivir Chem Chemother 1994; 5: 360-365.
167. Yokota T, Konno K, Shigeta S, Holy A, Balzarini J, De Clercq E. Inhibitory Effects of Acyclic Nucleoside Phosphonate Analogues on Hepatitis B Virus DNA Synthesis in Hb611 Cells, Antivir Chem Chemother 1994; 5: 57-63.
168. Dvoráková H, Holy A, Snoeck R, Balzarini J, De Clercq E. Acyclic nucleoside and nucleotide analogues derived from 1-deaza and 3-deazaadenine. Collect Czech Chem CommunSpec.Issue I 1990; 55: 113-116. VIIIth Symposium on the Chemistry of Nucleic Acids Components, Bechyne Castle, Czechoslovakia. September 17-21, 1990.
169. Gil-Fernandez C, Garcia-Villalon D, De Clercq E, Rosenberg I, Holy A. Phosphonylmethoxyalkylpurines and -pyrimidines as inhibitors of African swine fever virus replication in vitro. Antiviral Res 1987; 8: 273-281.
170. La Colla P, Holy A, Jindrich J, Dvoráková H, Gelli L, Marongiu ME, et al. Comparative antiviral activity of HPMPA, PMEA, HPMPG, HPMPC and structurally related compounds against African swine fever virus. Antiviral Res 1991; 15 Suppl. 1: 66-66.
171. Snoeck R, Andrei G, Holy A, De Clercq E. Activity of N6-substituted adenine and 2,6-diaminopurine acyclic nucleoside phosphonates against human cytomegalovirus (CMV) and other herpesviruses, Abstract Book 1997. 6th International Cytomegalovirus Workshop, Orange Beach, Alabama, USA. March 5-9, 1997.
172. Meerbach A, Holy A, Wutzler P, De Clercq E, Neyts J. Inhibitory effects of novel nucleoside and nucleotide analogues on Epstein-Barr virus replication. Antivir Chem Chemother 1998; 9: 275-282.
173. De Clercq E. Acyclic nucleoside phosphonates in the chemotherapy of DNA virus and retrovirus infections. Intervirology 1997; 40: 295-303.
174. Andrei G, Snoeck R, Goubau P, Desmyter J, De Clercq E. Comparative activity of various compounds against clinical strains of herpes simplex virus. Eur J Clin Microbiol Infect Dis 1992; 11: 143-151.
175. Andrei G, oeck R, Reymen D, Liesnard C, Goubau P, Desmyter J, et al. Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus. Eur J Clin Microbiol Infect Dis 1995; 14: 318-329.
176. Neyts J, De Clercq E. Antiviral drug susceptibility of human herpesvirus 8. Antimicrob Agents Chermother 1997; 41: 2754-2756.
177. de a Fuente R, Awan AR, Field HJ. The acyclic nucleoside analogue penciclovir is a potent inhibitor of equine herpesvirus type 1 (EHV-1) in tissue culture and in a murine model. Antiviral Res 1992, 18, 77-89.
178. Baba M, Mori S, Shigeta S, De Clercq E. Selective inhibitory effect of (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and 2′-nor-cyclic GMP on adenovirus replication in vitro. Antimicrob Agents Chemother 1987; 31: 337-339.
179. Gordon YJ, Romanowski F, Araullo-Cruz T, Seaberg L, Erzurum S, Tolman R, et al. Inhibitory effect of (S)-HPMPC, (S)-HPMPA, and 2′-nor-cyclic GMP on clinical ocular adenoviral isolates is serotype-dependent in vitro. Antiviral Res 1991; 16: 11-16.
180. Hitchcock MJ, Jaffe HS, Martin JC, Stagg RJ. Cidofovir, a new agent with potent anti-herpesvirus activity - Review: Antiviral protrait series. Antivir Chem Chemother 1996; 7: 115-127.
181. Naesens L, De Clercq E. Therapeutic potential of HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues as broad-spectrum antiviral agents. Nucleos Nucleot 1997; 16: 983-992.
182. De Clercq E. Towards an effective chemotherapy of virus infections: Therapeutic potential of cidofovir (S)-1-[3-hydroxy-2(phosphonomethoxy)propyl]cytosine, HPMPC] for the treatment of DNA virus infections. Collect Czech Chem Commun 1998; 63: 480-506.
183. Naesens L, Snoeck R, Andrei G, Balzarini J, Neyts J, De Clercq E. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: A review of their pharmacology and clinical potential in the treatment of viral infections. Antivir Chem Chemother 1997; 8: 1-23.
184. Balzarini J, Naesens L, Clercq ED. New antivirals - mechanism of action and resistance development. Curr Opin Microbiol 1998; 1: 535-546.
185. Zabawski EJ Jr, Cockerell CJ. Topical and intralesional cidofovir: a review of pharmacology and therapeutic effects. J Am Acad Dermatol 1998; 39: 741-745.
186. Cundy KC. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet 1999; 36: 127-143.
187. Wachsman M, Petty BG, Cundy KC, Jaffe HS, Fisher PE, Pastelak A, et al. Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects. Antiviral Res 1996; 29: 153-161.
188. Lalezari J, Schacker T, Feinberg J, Gathe J, Lee S, Cheung T, et al. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Dis 1997; 176: 892-898.
189. Plosker GL, Noble S. Cidofovir: a review of its use in cytomegalovirus retinitis in patients with AIDS. Drugs 1999; 58: 325-345.
190. Garcia CR, Torriani FJ, Freeman WR. Cidofovir in the treatment of cytomegalovirus (CMV) retinitis. Ocul Immunol Inflamm 1998; 6: 195-203.
191. Hoffman VF, Skiest DJ. Therapeutic developments in cytomegalovirus retinitis. Expert Opin Investig Drugs 2000; 9: 207-220.
192. Lewis RA, Carr LM, Doyle K, Fainstein V, Gross R, Orengonania S, et al. Long-term follow-up of patients with AIDS treated with parenteral cidofovir for cytomegalovirus retinitis: the HPMPC Peripheral Cytomegalo-virus Retinitis Trial - The Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. AIDS 2000; 14; 1571-1581.
193. Seijas M, Hernandez-Mora MD, Nodar A, Guerrero MLF. Cidofovir-induced severe alopecia. Revista Clin Espan 2000; 200: 584-586.
194. Kay TD, Hogan PG, McLeod S, Johnson DW. Severe irreversible proximal renal tubular acidosis and azotaemia secondary to cidofovir. Nephron 2000; 86: 348-349.
195. Berenguer J, Mallolas J. Intravenous cidofovir for compassionate use in AIDS patients with cytomegalovirus retinitis. Clin Infect Dis 2000; 30: 182-184.
196. Rougier MB, Neau D, Viallard JF, Ragnaud JM, Lacut Y, Korobelnik JF, et al. Anterior uveitis associated with cidofovir. J Fr Ophtalmol 2001; 24: 491-495.
197. Scott RAH, Pavesio C. Ocular side-effects from systemic HPMPC (cidofovir) for a non-ocular cytomegalovirus infection. Am J Ophthalmol 2000; 130: 126-127.
198. Lee TA, Sullivan SD, Veenstra DL, Ramsey SD, Steger PJK, Malinverni R, et al. Economic evaluation of systemic treatments for cytomegalovirus retinitis in patients with AIDS. Pharmacoeconomics 2001; 19: 535-550.
199. Bagnis C, Izzdine H, Deray G. Renal tolerance of cidofovir. Therapie 1999; 54: 689-691.
200. Lacy SA, Hitchcock MJ, Lee WA, Tellier P, Cundy KC. Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys. Toxicol Sci 1998; 44: 97-106.
201. Kiehl MG, Basara N. Cidofovir for cytomegalovirus-preemptive therapy in stem cell transplant recipients. Blood 2001; 98: 1626.
202. Chakrabarti S, Collingham KE, Osman H, Fegan CD, Milligan DW. Cidofovir as primary pre-emptive therapy for posttransplant cytomegalovirus infections. Bone Marrow Transplant 2001; 28: 879-881.
203. Safrin S, Cherrington J, Jaffe HS. Cidofovir. Review of current and potential clinical uses. Adv Exp Med Biol 1999; 458: 111-120.
204. Snoeck R, Andrei G, Gerard M, Silverman A, Hedderman A, Balzarini J, et al. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). Clin Infect Dis 1994; 18: 570-578.
205. Javaly K, Wohlfeiler M, Kalayjian R, Klein T, Bryson Y, Grafford K, et al. Treatment of mucocutaneous herpes simplex virus infections unresponsive to acyclovir with topical foscarnet cream in AIDS patients: A phase I/II study. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 21: 301-306.
206. Leung DT, Sacks SL. Current recommendations for the treatment of genital herpes. Drugs 2000; 60: 1329-1352.
207. Kopp T, Geusau A, Rieger A, Stingl G. Successful treatment of an aciclovir-resistant herpes simplex type 2 infection with cidofovir in an AIDS patient. Brit J Dermatol 2002; 147: 134-138
208. Van Cutsem E, Snoeck R, Van Ranst M, Fiten P, Opdenakker G, Geboes K, et al. Successful treatment of a squamous papilloma of the hypopharynx - esophagus by local injections of (S)-1-(3-hydroxy-2-phos-phonylmethoxypropyl)cytosine. J Med Virol 1995; 45: 230-235.
209. Bielamowicz S, Villagomez V, Stager SV, Wilson WR. Intralesional cidofovir therapy for laryngeal papilloma in an adult cohort. Laryngoscope 2002; 112: 696-699.
210. Chhetri DK, Blumin JH, Shapiro NL, Berke GS. Office-based treatment of laryngeal papillomatosis with percutaneous injection of cidofovir. Otolaryngol Head Neck Surg 2002; 126: 642-648.
211. Snoeck R, Bossens M, Parent D, Delaere B, Degreef H, VanRanst M, et al. Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection. Clin Infect Dis 2001; 33: 597-602.
212. Orlando G, Fasolo MM, Beretta R, Merli S, Cargnel A. Combined surgery and cidofovir is an effective treatment for genital warts in HIV-infected patients. AIDS 2002; 16: 447-450.
213. Snoeck R, Wellens W, Desloovere C, Van Ranst M, Naesens L, De Clercq E, Feenstra L. Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine]. J Med Virol 1998; 54: 219-225.
214. Pransky SM, Magit AE, Kearns DB, Kang DR, Duncan NO. Intralesional cidofovir for recurrent respiratory papillomatosis in children. Arch Otolaryngol Head Neck Surg 1999; 125: 1143-1148.
215. Pransky SM, Brewster DF, Magit AE, Kearns DB. Clinical update on 10 children treated with intralesional cidofovir injections for severe recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2000; 126: 1239-1243.
216. Armbruster C, Kreuzer A, Vorbach H, Huber M, Armbruster C. Successful treatment of severe respiratory papillomatosis with intravenous cidofovir and interferon α-2b. Eur Resp J 2001; 17: 830-831.
217. Van Valckenborgh I, Wellens W, De Boeck K, Snoeck R, De Clercq E, Feenstra L. Systemic cidofovir in papillomatosis. Clin Infect Dis 2001; 32: E62-E64.
218. Orlando G, Fasolo MM, Beretta R, Signori R, Adriani B, Zanchetta N, et al. Intralesional or topical cidofovir (HPMPC, Vistide) for the treatment of recurrent genital warts in HIV-1-infected patients [letter]. AIDS 1999; 13: 1978-1980.
219. Matteelli A, Beltrame A, Graifemberghi S, Forleo MA, Gulletta M, Ciravolo G, et al. Efficacy and tolerability of topical 1% cidofovir cream for the treatment of external anogenital warts in HIV-infected persons. Sex Transm Dis 2001; 28: 343-346.
220. Calista D. Resolution of recalcitrant human papillomavirus gingival infection with topical cidofovir, Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics 2000; 90: 713-715.
221. Dancey DR, Chamberlain DW, Krajden M, Palefsky J, Alberti PW, Downey GP. Successful treatment of juvenile laryngeal papillomatosis-related multicystic lung disease with cidofovir - Case report and review of the literature. Chest 2000; 118: 1210-1214.
222. Davis MDP, Gostout BS, McGovern RM, Persing DH, Schut RL, Pittelkow MR. Large plantar wart caused by human papillomavirus-66 and resolution by topical cidofovir therapy. J Am Acad Dermatol 2000; 43: 340-343.
223. Hengge UR, Tietze G. Successful treatment of recalcitrant condyloma with topical cidofovir. Sex Transm Infect 2000; 76: 143-143.
224. Schurmann D, Bergmann F, Temmesfeld-Wollbruck B, Grobusch MP, Suttorp N. Topical cidofovir is effective in treating extensive penile condylomata acuminata. AIDS 2000; 14: 1075-1076.
225. Descamps V, Duval X, Grossin M, Crickx B, Leport C. Topical cidofovir for bowenoid papulosis in an HIV-infected patient. Brit J Dermatol 2001; 144: 642-643.
226. Happe S, Besselmann M, Matheja P, Rickert CH, Schuierer G, Reichelt D, et al. [Cidofovir (Vistide) in therapy of progressive multilfocal leukoencephalopathy in AIDS. Review of the literature and report of 2 cases]. Nervenarzt 1999; 70: 935-943.
227. Happe S, Lunenborg N, Rickert CH, Heese C, Reichelt D, Schuierer G, et al. [Progressive multifocal leukoencephalopathy in AIDS. Overview and retrospective analysis of 17 patients]. Nervenarzt 2000; 71: 96-104.
228. Gasnault J, Kousignian P, Kahraman M, Rahoiljaon J, Matheron S, Delfraissy JF, et al. Cidofovir in AIDS-associated progressive multifocal leukoencephalopathy: A monocenter observational study with clinical and JC virus load monitoring. J Neurovirol 2001; 7: 375-381.
229. Marra CM, Rajicic N, Barker DE, Cohen BA, Clifford D, Post MJD, et al. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS 2002; 16: 1791-1797.
230. Cardenas RL, Cheng KH, Sack K. The effects of cidofovir on progressive multifocal leukoencephalopathy: an MRI case study, Neuroradiology 2001; 43: 379-382.
231. Segarra-Newnham M, Vodolo KM. Use cidofovir in progressive multifocal leukoencephalopathy. Ann Pharmacother 2001; 35: 741-744.
232. Martinez AC, Lopez AG, Garcia IG. Successful resolution of progressive multifocal leukoencephalopathy after combination therapy with cidofovir and cytosine arabinoside. Clin Infect Dis 2000; 30: 234-234.
233. Herrero-Romero M, Cordero E, López-Cortés LF, de Alarcón A, Pachón J. Cidofovir added to highly active antiretroviral therapy in AIDS-associated progressive multifocal leukoencephalopathy. AIDS 2001; 15: 809.
234. Razonable RR, Aksamit AJ, Wright AJ, Wilson JW, Cidofovir treatment of progressive multifocal leukoencephalopathy in a patient receiving highly active antiretroviral therapy. Mayo Clin Proc 2001; 76: 1171-1175.
235. Portilla J, Boix V, Román F, Reus S, Merino E. Progressive multifocal leukoencephalopathy treated with cidofovir in HIV-infected patients receiving highly active antiretroviral therapy. J Infect 2000; 41: 182-184.
236. Ibarra V, Blanco JR, Oteo JA, Rosel L. Efficacy of cidofovir in the treatment of recalcitrant molluscum contagiosum in an AIDS patient, Acta Dermato-Venerol. 2000; 80: 315-316;
237. Davies EG, Thrasher A, Lacey K, Harper J. Topical cidofovir for severe molluscum contagiosum. Lancet 1999; 353: 2042-2042.
238. Toro JR, Wood LV, Patel NK, Turner ML. Topical cidofovir - A novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus 1. Arch Dermatol 2000; 136: 983-985.
239. Geerinck K, Lukito G, Snoeck R, DeVos R, DeClercq E, Vanrenterghem Y, et al. A case of human orf in an immunocompromised patient treated successfully with cidofovir cream. J Med Virol 2001; 64: 543-549.
240. Bray M, Martinez M, Smee DF, Kefauver D,Thompson E, Huggins JW, et al. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J Infect Dis 2000; 181: 10-19.
241. Smee DF, Bailey KW, Wong M, Sidwell RW. Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice. Antiviral Res. 2001; 52: 55-62.
242. Bray M, Martinez M, Kefauver D, West M, Roy C. Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir. Antivir Res 2002; 54: 129-142.
243. DeClercq E. Cidofovir in the therapy and short-term prophylaxis of poxvirus infections. Trends Pharmacol Sci 2002; 23: 456-458.
244. Smee DF, Bailey KW, Sidwell RW. Treatment of cowpox virus respiratory infections in mice with ribavirin as a single agent or followed sequentially by cidofovir. Antivir Chem Chemother 2000; 11: 303-309;
245. Smee DF, Bailey KW, Wong MH, Sidwell RW. Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir. Antiviral Res 2000; 47: 171-177.
246. Ljungman P, Ribaud P, Matthes-Martin S, Eyrich M, Bierings M, Macharczka M, et al. Cidofovir for adenovirus infection after allogeneic Stem Cell Transplantation (SCT). A retrospective survey of the infectious diseases working party of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2001; 27: S61;
247. Ljungman P, Deliliers GL, Platzbecker U, Matthes-Martín S, Bacigalupo A, Einsele H, et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. Blood 2001; 97: 388-392.
248. Gordon YJ, Naesens L, De Clercq E, Maudgal PC, Veckeneer M. Treatment of adenoviral conjunctivitis with topical cidofovir. Cornea 1996; 15: 546-546.
249. Romanowski EG, Gordon YJ. Efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand rabbit ocular model. Invest Ophthalmol Visual Sci 2000; 41: 460-463.
250. Romanowski EG, Yates KA, Gordon YJ. Antiviral prophylaxis with twice daily topical cidofovir protects against challenge in the adenovirus type 5/New Zealand rabbit ocular model Antiviral Res 2001; 52: 275-280.
251. Ribaud P, Scieux C, Freymuth F, Morinet F, Gluckman E. Successful treatment of adenovirus disease with intravenous cidofovir in an unrelated stem-cell transplant recipient. Clin Infect Dis 1999; 28: 690-691.
252. Hayashi M, Lee CK, deMagalhaes-Silverman M, Becker A, Scott S, Gingrich RD. Adenovirus infection in BMT patients successfully treated with cidofovir. Blood 2000; 96: 810.
253. Hoffman JA, Kapoor N, Crooks GM, Kohn DB, Parkman R, Shah AJ, et al. Cidofovir for treatment of adenoviral infections in pediatric hematopoietic stem cell transplant recipients. Clin Infect Dis 2000; 31: 614.
254. Kapoor N, Shah AJ, Hoffman J, Crooks GM, Kohn DB, Weinberg KI, et al. Cidofovir for treatment of adenoviral infections in pediatric hematopoietic stem cell transplant recipients. Blood 2000; 96: 812.
255. Hillenkamp J, Reinhard T, Cartsburg O, Sundmacher R, Ross RS, Roggendorf M, et al. Topical treatment of adenoviral kerato-conjunctivitis with Cidofovir and Cyclosporin A. A clinical pilot study. Investig Ophthalmol Vis Sci 2000; 41: 1366B741.
256. Legrand F, Berrebi D, Houhou N, Freymuth F, Faye A, Duval M, et al. Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children. Bone Marrow Transplant 2001; 27: 621-626.
257. Fife K, Gill J, Bourboulia D, Gazzard B, Nelson M, Bower M, et al. Cidofovir for the treatment of Kaposi's sarcoma in an HIV-negative homosexual man. Brit J Dermatol 1999; 141: 1148-1150.
258. Simonart T, Noel JC, Dedobbeleer G, Parent D, Vanvooren JP, De Clercq E, et al. Treatment of classical Kaposi's sarcoma with intralesional injections of cidofovir: Report of a case. J Med Virol 1998, 55: 215-218.
259. Held TK, Biel SS, Nitsche A, Kurth A, Chen S, Gelderblom HR, et al. Treatment of BK virus-associated hemorrhagic cystitis and simultaneous CMV reactivation with cidofovir. Bone Marrow Transplant 2000; 26: 347-350.
260. Johnson JA, Gangemi JD. Selective inhibition of human papillomavirus-induced cell proliferation by (S)-1-3-hydroxy-2(phosphonylmethoxy)propyl]cytosine. Antimicrob Agents Chemother 1999; 43: 1198-1205.
261. Andrei G, Snoeck R, Piette J, Delvenne P, De Clercq E. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV- negative cell lines. Oncol Res 1998, 10:523-531.
262. Yoshida M, Yamada M, Tsukazaki T, Chatterjee S, Lakeman FD, Nii S, et al. Comparison of antiviral compounds against human herpesvirus 6 and 7. Antiviral Res 1998; 40: 73-84.
263. Neyts J, De Clercq E. Antiviral drug susceptibility of human herpesvirus 8, Antimicrob. Agents Chemother 1997; 41: 2754-2756.
264. Ljungman P. Prophylaxis against herpesvirus infections in transplant recipients. Drugs 2001; 61: 187-196.
265. Nebbia G, Mattes FM, Potter M, Prentice HG, Ethell M, Griffiths PD. Use of intravenous cidofovir for the treatment of adenovirus infection in pre/post bone marrow transplant patients. Bone Marrow Transplant 2001; 27: S207.
266. Platzbecker U, Bandt D, Thiede C, Helwig A, Freiberg-Richter J, Schuler U, et al. Successful preemptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation. Transplant 2001; 71: 880-885.
267. Ullmann J, Ledderose G, Jaeger G, Kolb HJ. EBV-infection/disease in allogeneic stem cell transplantation and Cidofovir (CDF) treatment. Bone Marrow Transplant 2001; 27:, S208-S209.
268. Balzarini J, Vahlenkamp T, Egberink HF, Hartmann K, Witwrouw M, Pannecouque C, et al. Antiretroviral activities of acyclic nucleoside phosphonates 9-(2-phosphonyl-methoxyethyl)adenine, 9-(2-phosphonylmethoxyethyl)guanine, (R)-9-(2-phosphonylmethoxypropyl)adenine, and MDL 74,968] in cell cultures and murine sarcoma virus-infected newborn NMRI mice. Antimicrob Agents Chemother 1997; 41: 611-616.
269. Cundy KC, Shaw JP, Lee WA. Oral subcutaneous, and intramuscular bioavailabilities of the antiviral nucleotide analog 9-(2-phosphonylmethoxyethyl) adenine in cynomolgus monkeys. Antimicrob Agents Chemother 1994; 38: 365-368.
270. Cundy KC, Sue IL, Visor GC, Marshburn J, Nakamura C, Lee WA, et al. Oral formulations of adefovir dipivoxil: in vitro dissolution and in vivo bioavailability in dogs. J Pharm Sci 1997; 86: 1334-1338.
271. Cundy KC, Fishback JA, Shaw JP, Lee ML, Soike KF, Visor GC, et al. Oral bioavailability of the antiretroviral agent 9-(2-phosphonylmethoxyethyl)adenine (PMEA) from three formulations of the prodrug bis(pivaloyloxymethyl)-PMEA in fasted male cynomolgus monkeys. Pharm Res 1994; 11: 839-843.
272. Shulman NS, Zolopa AR, Passaro DJ, Murlidharan U, Israelski DM, Brosgart CL, et al. Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: Clinical and genotypic predictors of virologic response. J Acquir Immune Defic Syndr Hum Retrovirol 2000; 23: 221-226.
273. Naesens L, Balzarini J, Bischofberger N, De Clercq E. Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl) adenine. Antimicrob Agents Chemother 1996; 40: 22-28.
274. Naesens L, Neyts J, Balzarini J, Bischofberger N, De Clercq E. In vivo antiretroviral efficacy of oral bis(POM)-PMEA, the bis(pivaloyloxymethyl)prodrug of 9-(2-phosphonylmethoxyethyl) adenine (PMEA). Nucleos Nucleot 1995; 14: 767-770.
275. Tsai CC, Follis KE, Sabo A, Grant R, Bischofberger N. Efficacy of 9-(2-phosphonylmethoxyethyl)adenine treatment against chronic simian immunodeficiency virus infection in macaques. J Infect Dis 1995; 171: 1338-1343.
276. Cundy KC, Barditch-Crovo P, Walker RE, Collier AC, Ebeling D, Toole J, et al. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 1995; 39: 2401-2405.
277. Deeks SG, Collier A, Lalezari J, Pavia A, Rodrigue D, Drew WL, et al. The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. J Infect Dis 1997; 176: 1517-1523.
278. Colledge D, Civitico G, Locarnini S, Shaw T. In vitro antihepadna-viral activities of combinations of penciclovir, lamivudine, and adefovir. Antimicrob Agents Chemother 2000; 44: 551-560;
279. Delmas J, Schorr O, Jamard C, Gibbs C, Trepo C, Hantz O, et al. Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro. Antimicrob Agents Chemother 2002; 46: 425-433.
280. Cullen JM, Li DH, Brown C, Eisenberg EJ, Cundy KC, Wolfe J, et al. Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks. Antimicrob Agents Chemother 2001; 45: 2740-2745.
281. Nicoll A, Locarnini S. Review: Present and future directions in the treatment of chronic hepatitis B infection. J Gastroenterol Hepatol 1997; 12: 843-854.
282. Benhamou Y, Bochet M, Thibault V, Calvez V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001; 358: 718-723;
283. Delaugerre C, Marcelin AG, Thibault V, Peytavin G, Bombled T, Bochet MV, et al. Human immunodeficiency virus (HIV) type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine. Antimicrob Agents Chemother 2002; 46: 1586-1588;
284. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32: 129-134.
285. Mutimer D, Feraz-Neto BH, Harrison R, O'Donnell K, Shaw J, Cane P, et al. Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir. Gut 2001; 49: 860-863;
286. Walsh KM, Woodall T, Lamy P, Wight DGD, Bloor S, Alexander GJM. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. Gut 2001; 49: 436-440.
287. Naesens L, Balzarini J, De Clercq E. Therapeutic potential of PMEA as an antiviral drug. Rev Med Virol 1994; 4: 147-159.
288. Noble S, Goa KL. Adefovir dipivoxil. Drugs 1999; 58: 479-487.
289. De Clercq E. Perspectives for the treatment of hepatitis B virus infections. Int J Antimicrob Agents 1999; 12: 81-95.
290. Naesens L, Neyts J, Balzarini J, Holy A, Rosenberg I, De Clercq E. Efficacy of oral 9-(2-phosphonylmethoxyethyl)-2,6-diamino-purine (PMEDAP) in the treatment of retrovirus and cytomegalo-virus infections in mice. J Med Virol 1993; 39: 167-172.
291. Naesens L, Balzarini J, Rosenberg I, Holy A, De Clercq E. 9-(2-Phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP): a novel agent with anti-human immunodeficiency virus activity in vitro and potent anti-Moloney murine sarcoma virus activity in vivo. Eur J Clin Microbiol Infect Dis 1989; 8: 1043-1047.
292. Naesens L, Balzarini J, De Clercq E. Single-dose administration of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) and 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) in the prophylaxis of retrovirus infection in vivo. Antiviral Res 1991; 16: 53-64.
293. Suo Z, Johnson KA. Selective Inhibition of HIV-1 Reverse Transcriptase by an Antiviral Inhibitor, (R)-9-(2-Phosphonylmethoxypropyl)adenine. Biol Chem 1998; 273: 27250-27258.
294. Cihlar T, Birkus G, Greenwalt DE, Hitchcock MJM. Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. Antivir Res 2002; 54: 37-45.
295. Srinivas RV, Fridland A. Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strains. Antimicrob Agents Chemother 1998; 42: 1484-1487.
296. Suruga Y, Makino M, Okada Y, Tanaka H, De Clercq E, Baba M. Prevention of murine AIDS development by (R)-9-(2-phosphonylmethoxypropyl)adenine, J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18: 316-322.
297. Tsai CC, Follis KE, Sabo A, Beck TW, Grant RF, Bischofberger N, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 1995; 270: 1197-1199.
298. Van Rompay KK, Cherrington JM, Marthas ML, Berardi CJ, Mulato AS, Spinner A, et al. 9-2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob Agents Chemother 1996; 40: 2586-2591.
299. Tsai CC, Follis KE, Beck TW, Sabo A, Bischofberger N, Dailey PJ. Effects of (R)-9-(2-phosphonylmethoxypropyl) adenine monotherapy on chronic SIV infection in macaques. AIDS Res Hum Retroviruses 1997; 13: 707-712.
300. Silvera P, Racz P, Racz K, Bischofberger N, Crabbs C, Yalley-Ogunro J, et al. Effect of PMPA and PMEA on the kinetics of viral load in simian immunodeficiency virus-infected macaques. AIDS Res Hum Retroviruses 2000; 16: 791-800.
301. Tsai CC, Emau P, Follis KE, Beck TW, Benveniste RE, Bischofberger N, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998; 72: 4265-4273.
302. Van Rompay KK, Dailey PJ, Tarara RP, Canfield DR, Aguirre NL, Cherrington JM, et al. Early short-term 9-[2-(R)-(phosphonomethoxy) propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn Rhesus macaques. J Virol 1999; 73: 2947-2955.
303. Hodge S, de Rosayro J, Glenn A, Ojukwu IC, Dewhurst S, McClure HM, et al. Postinoculation PMPA treatment, but not preinoculation immunomodulatory therapy, protects against development of acute disease induced by the unique simian immunodeficiency virus SIVsmmPBj. J Virol 1999; 73: 8630-8639.
304. Van Rompay KK, Cherrington JM, Marthas ML, Lamy PD, Dailey PJ, Canfield DR, et al. 9-2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA. Antimicrob Agents Chemother 1999; 43: 802-812.
305. Rosenwirth B, Ten Haaft P, Bogers WM, Nieuwenhuis IG, Niphuis H, Kuhn EM, et al. Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques. J Virol 2000; 74: 1704-1711.
306. Smith MS, Foresman L, Lopez GJ, Tsay J, Wodarz D, Lifson JD,
307. Tarantal AF, Marthas ML, Shaw JP, Cundy K, Bischofberger N. Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 323-333.
308. Van Rompay KK, Miller MD, Marthas ML, Margot NA, Dailey PJ, Canfield DR, et al. Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl] adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA. J Virol 2000; 74: 1767-1774.
309. Kumar A, Buch S, Foresman L, Bischofberger N, Lifson JD, Narayan O. Development of virus-specific immune responses in SHIVKU-infected macaques treated with PMPA. Virology 2001; 279: 97-108.
310. Van Rompay KK, Marthas ML, Lifson JD, Berardi CJ, Vasquez GM, Agatep E, et al. Administration of 9-[2-(phosphonomethoxy)-propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques. AIDS Res Hum Retroviruses 1998; 14: 761-773.
311. Otten RA, Smith DK, Adams DR, Pullium JK, Jackson E, Kim CN, et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol 2000; 74: 9771-9775.
312. Cundy KC, Sueoka C, Lynch GR, Griffin L, Lee WA, Shaw JP. Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Antimicrob Agents Chemother 1998; 42: 687-690.
313. Deeks SG, Barditch-Crovo P, Lietman PS, Hwang F, Cundy KC, Rooney JF, et al. Safety, pharmaco-kinetics, and antiretroviral activity of intravenous 9- [2-(R)-(Phosphonomethoxy)propyl] adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob Agents Chemother 1998; 42: 2380-2384;
314. Barditch-Crovo P, Deeks SG, Collier A, Safrin S, Coakley DF, Miller M, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunode-ficiency virus-infected adults. Antimicrob Agents Chemother 2001; 45: 2733-2739.
315. Robbins BL, Srinivas RV, Kim C, Bischofberger N, Fridland A. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA). Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother 1998; 42: 612-617;
316. Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, Berger D, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002; 16: 1257-1263.
317. Mulato AS, Cherrington JM. Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses. Antiviral Res 1997; 36: 91-97.
318. Smeijsters LJ, Franssen FF, Naesens L, de Vries E, Holy A, Balzarini J, et al. Inhibition of the in vitro growth of Plasmodium falciparum by acyclic nucleoside phosphonates. Int J Antimicrob Agents 1999; 12: 53-61.
319. de Vries E, Stam JG, Franssen FF, Nieuwenhuijs H, Chavalitshewinkoon P, De Clercq E, et al. Inhibition of the growth of Plasmodium falciparum and Plasmodium berghei by the DNA polymerase inhibitor HPMPA. Mol Biochem Parasitol 1991; 47: 43-50.
320. Smeijsters LJJW, Zijlstra NM, Veenstra J, Verstrepen BE, Heuvel C, Overdulve JP, et al. Plasmodium falciparum clones resistant to (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine carry amino acid substitutions in DNA polymerase δ. Mol Biochem Parasitol 2000; 106: 175-180.
321. Smeijsters LJ, Zijlstra NM, de Vries E, Franssen FF, Janse CJ, Overdulve JP. The effect of (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl) adenine on nuclear and organellar DNA synthesis in erythrocytic schizogony in malaria. Mol Biochem Parasitol 1994; 67: 115-124.
322. Smeijsters LJ, Nieuwenhuijs H, Hermsen RC, Dorrestein GM, Franssen FF, Overdulve JP. Antimalarial and toxic effects of the acyclic nucleoside phosphonate (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine in Plasmodium berghei-infected mice Antimicrob Agents Chemother 1996; 40: 1584-1588.
323. Kaminsky R, Zweygarth E, De Clercq E. Antitrypanosomal activity of phosphonylmethoxyalkylpurines. J Parasitol 1994; 80: 1026-1030.
324. Kaminsky R, Schmid C, Grether Y, Holy A, De Clercq E, Naesens L, et al. (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine [(S)-HPMPA]: a purine analogue with trypanocidal activity in vitro and in vivo. Trop Med Int Health 1996; 1: 255-263.
325. Kaminsky R, Nickel B, Holy A. Arrest of Trypanosoma brucei rhodesiense and T-brucei brucei in the S-phase of the cell cycle by (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine ((S)-HPMPA). Mol Biochem Parasitol 1998; 93: 91-100.
326. Vesely J, Merta A, Votruba I, Rosenberg I, Holy A. The cytostatic effects and mechanism of action of antiviral acyclic adenine nucleotide analogs in L1210 mouse leukemia cells. Neoplasma 1990; 37: 105-110.
327. Rose WC, Crosswell AR, Bronson JJ, Martin JC. In vivo antitumor activity of 9-(2-phosphonylmethoxy)ethyl]guanine and related phosphonate nucleotide analogues. J Natl Cancer Inst 1990; 82: 510-512.
328. Otová B, Sladká M, Blazek K, Schramlova J, Votruba I, Holy A. Cytostatic effect of 9-(2-phosphonomethoxyethyl) adenine (PMEA). II. Lymphoblastic leukemia in Sprague-Dawley rats. Folia Biol Prague 1993; 39: 142-149.
329. Otová B, Sladká M, Votruba I, Holy A, Kren V. Cytostatic effect of 9-(2-phosphonomethoxyethyl)adenine (PMEA). I. Lymphatic leukemia KHP-Lw-I in Lewis rats. Folia Biol Prague 1993; 39: 136-141.
330. Otová B, Krenová D, Zídek Z, Holy A, Votruba I, Kren V. Cytostatic effect of 9-(2-phosphonomethoxyethyl)adenine (PMEA). III. Rat and mouse carcinomas and sarcomas. Folia Biol Prague 1993; 39: 311-314.
331. Hatse S, Balzarini J, De Clercq E. Induction of erythroid differentiation of human leukemia K562 cells by the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl)adenine (PMEA). Nucleos Nucleot 1995; 14: 649-652.
332. Hatse S, De Clercq E, Balzarini J. Evidence for distinction of the differentiation-inducing activities and cytostatic properties of 9-(2-phosphonylmethoxyethyl)adenine and a variety of differentiation-inducing agents in human erythroleukemia K562 cells. Mol Pharmacol 1996; 50: 1231-1242.
333. Hatse S, Schols D, De Clercq E, Balzarini J. 9-(2-phosphonylmethoxyethyl)adenine induces tumor cell differentiation or cell death by blocking cell cycle progression through the S phase. Cell Growth Differ 1999; 10: 435-446.
334. Hatse S, Naesens L, Degreve B, Vandeputte M, Waer M, Clercq ED, et al. In vitro and in vivo inhibitory activity of the differentiation- inducing agent 9-(2-phosphonylmethoxyethyl)adenine (PMEA) against rat choriocarcinoma. Adv Exp Med Biol 1998; 431: 605-609.
335. Hatse S, Naesens L, Degreve B, Segers C, Vandeputte M, Waer M, et al. Potent antitumor activity of the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl)adenine in choriocarcinoma-bearing rats. Int J Cancer 1998; 76: 595-600.
336. Bobková K, Otová B, Marinov I, Mandys V, Panczak A, Votruba I, et al. Anticancer effect of PMEDAP - Monitoring of apoptosis. Anticancer Res 2000; 20: 1041-1047.
337. Otová B, Francová K, Franek F, Koutník P, Votruba I, Holy A, et al. 9-2-(phosphonomethoxy)ethyl]-2,6-diaminopurine (PMEDAP) - a potential drug against hematological malignancies - induces apoptosis. Anticancer Res 1999; 19: 3173-3182.
338. Bobková K, Gut I, Mandys V, Holy A, Votruba I, Otová B. Antitumour activity of a combined treatment with PMEDAP and docetaxel in the Prague inbred Sprague-Dawley/cub rat strain bearing T-cell lymphoma. Anticancer Res. in press.
339. Franek F, Holy A, Votruba I, Eckschlager T. Acyclic nucleotide analogues suppress growth and induce apoptosis in human leukemia cell lines. Int J Oncol 1999; 14: 745-752.
340. Otová B, Zídek Z, Holy A, Votruba I, Sladka M, Marinov I, et al. Antitumor activity of novel purine acyclic nucleotide analogs PMEA and PMEDAP. In Vivo 1997; 11: 163-167.
341. Compton ML, Toole JJ, Paborsky LR. 9-(2-Phosphonylmethoxy-ethyl)-N6-cyclopropyl-2,6-diaminopurine (cpr-PMEDAP) as a prodrug of 9-(2-phosphonylmethoxyethyl)guanine (PMEG). Biochem Pharmacol 1999; 58: 709-714.
342. Hatse S, Naesens L, De Clercq E, Balzarini J. N-6-cyclopropyl-PMEDAP: A novel derivative of 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) with distinct metabolic, antiproliferative, and differentiation- inducing properties. Biochem Pharmacol 1999; 58; 311-323.
343. Valeriánová M, Votruba I, Holy A, Mandys V, Otová B. Antitumour activity of N-6-substituted PMEDAP derivatives against T-cell lymphoma. Anticancer Res 2001; 21: 2057-2064.
344. Snoeck R, Noel JC, Muller C, De Clercq E, Bossens M. Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III). J Med Virol 2000; 60: 205-209.
345. Andrei G, Snoeck R, Piette J, Delvenne P, De Clercq E. Inhibiting effects of cidofovir (HPMPC) on the growth of the human cervical carcinoma (SiHa) xenografts in athymic nude mice. Oncol Res 1998; 10: 533-539.
346. Redondo P, Idoate M, Galofré JC, Solano T. Cidofovir inhibits growth of B16 melanoma cells in vivo. Brit J Dermatol 2000; 143: 741-748.
347. Liekens S, Andrei G, Vandeputte M, De Clercq E, Neyts J. Potent inhibition of hemangioma formation in rats by the acyclic nucleoside phosphonate analogue cidofovir. Cancer Res 1998; 58: 2562-2567.
348. Calista D, Riccioni L, Coccia L. Successful treatment of squamous cell carcinoma of the lower eyelid with intralesional cidofovir. Br J Ophthalmol 2002; 86: 932-933.
349. Sherman MD, Feldman KA, Farahmand SM, Margolis TP. Treatment of conjunctival squamous cell carcinoma with topical cidofovir. Amer J Ophthalmol 2002; 134: 432-433.
350. Liekens S, Verbeken E, De Clercq E, Neyts J. Potent inhibition of hemangiosarcoma development in mice by cidofovir. Int. J Cancer 2001; 92: 161-167.
351. Neyts J, Sadler R, De Clercq E, Raab-Traub N, Pagano JS. The antiviral agent cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine] has pronounced activity against nasopharyngeal carcinoma grown in nude mice. Cancer Res 1998; 58: 384-388.
352. Otová B, Holy A, Votruba I, Sladká M, Bilá V, Mejsnarová B, et al. Genotoxicity of purine acyclic nucleotide analogs. Folia Biol Prague 1997; 43: 225-229.
353. Hanel M, Fiedler F, Thorns C. Anti-CD20 Monoclonal Antibody (Rituximab) and Cidofovir as Successful Treatment of an EBV-Associated Lymphoma with CNS Involvement. Onkologie 2001; 24; 491-494.
354. Bilá V, Otová B, Jelínek R, Sladká M, Mejsnarová B, Holy A, et al. Antimitotic and teratogenic effects of acyclic nucleotide analogues 1-(S)-(3-hydroxy-2-phosphonomethoxyethyl)cytosine (HPMPC) and 9-(2-phosphonomethoxyethyl) adenine (PMEA). Folia Biol Prague 1993; 39: 150-161.
355. Calio R, Villani N, Balestra E, Sesa F, Holy A, Balzarini J, et al. Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates. Antiviral Res 1994; 23: 77-89.
356. Del Gobbo V, Foli A, Balzarini J, De Clercq E, Balestra E, Villani N, et al. Immunomodulatory activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA), a potent anti-HIV nucleotide analogue, on in vivo murine models. Antiviral Res 1991; 16: 65-75.
357. Villani N, Calio R, Balestra E, Balzarini J, De Clercq E, Fabrizi E, et al. 9-(2-Phosphonylmethoxyethyl) adenine increases the survival of influenza virus-infected mice by an enhancement of the immune system. Antiviral Res 1994, 25: 81-89.
358. Zídek Z, Holy A, Franková D. Immunomodulatory properties of antiviral acyclic nucleotide analogues: Cytokine stimulatory and nitric oxide costimulatory effects. Int J Immunopharmacol 1997; 19: 587-597.
359. Zídek Z, Franková D, Holy A. Stimulation of cytokine and nitric oxide production by acyclic nucleoside phosphonates. Nucleos Nucleot 1999; 18: 959-961.
360. Zídek Z, Franková D, Holy A. Macrophage activation by antiviral acyclic nucleoside phosphonates in dependence on priming immune stimuli. Int J Immunopharmacol 2000; 22: 1121-1129.
361. Zídek Z, Holy A, Franková D. Antiretroviral agent (R)-9-(2-phosphonomethoxypropyl)adenine stimulates cytokine and nitric oxide production. Eur J Pharmacol 1997; 331: 245-252.
362. Kren V, Otová B, Elleder D, Elleder M, Panczak A, Holy A. Prevention of acute graft-versus-host disease in rats using 9-(2-phosphonomethoxyethyl) adenine (PMEA). Folia Biol Prague 1993; 39: 78-86.
363. Otová B, Zídek Z, Holy A, Votruba I, Franková D. Immunomodulatory properties of 9-(2-phosphonomethoxyethyl)adenine (PMEA). Folia Biol Prague 1994; 40: 185-192.
364. Zídek Z, Franková D, Holy A, Boubelik M, Dráber P. Inhibition of murine macrophage nitric oxide synthase expression by a pivoxil prodrug of antiviral acyclic nucleotide analogue 9-(2-phosphonomethoxyethyl)adenine. Biochem Pharmacol 1997; 54: 855-861.
365. Zídek Z, Holy A, Franková D, Otová B. Suppression of rat adjuvant arthritis by some acyclic nucleotide analogs. Eur J Pharmacol 1995; 286: 307-310.
366. Zídek Z, Franková D, Holy A. Chemokines, nitric oxide and antiarthritic effects of 9-(2-phosphonomethoxyethyl)adenine (Adefovir). Eur J Pharmacol 1999; 376: 91-100.
367. Zídek Z, Franková D, Holy A. Activation by 9-(R)-[2-(phosphonomethoxy)propyl]adenine of chemokine (RANTES, macrophage inflammatory protein 1α) and cytokine (tumor necrosis factor alpha, interleukin-10 [IL-10], IL-1β) production. Antimicrob Agents Chemother 2001; 45: 3381-3386.
368. Breman JG, Henderson DA. Current concepts - Diagnosis and management of smallpox. N Engl J Med 2002; 346: 1300-1308.
369. Oliyai R, Arimilli MN, Jones RJ, Lee WA. Pharmacokinetics of salicylate ester prodrugs of cyclic HPMPC in dogs. Nucleos Nucleot Nucleic Acids 2001; 20: 1411-1414.
370. Beadle JR, Hartline C, Aldern KA, Rodriguez N, Harden E, Kern ER, et al. Alkoxyalkyl Esters of Cidofovir and Cyclic Cidofovir Exhibit Multiple-Log Enhancement of Antiviral Activity against Cytomegalovirus and Herpesvirus Replication In Vitro. Antimicrob Agents Chemother 2002; 46: 2381-2386.
371. Kern ER, Hartline C, Harden E, Keith K, Rodriguez N, Beadle JR, et al. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob Agents Chemother 2002; 46: 991-995.
372. Bradbury J. Orally available cidofovir derivative active against smallpox. Lancet 2002; 359: 1041.
373. Huggins JW, Baker RO, Beadle JR, Hostetler KY. Orally Active Ether Lipid Prodrugs of Cidofovir for the Treatment of Smallpox. Poster # 104. XV International Conference on Antiviral Research, Prague, Czech Republic. March 17-21, 2002. Antiviral Res 2002; 53: A66.
374. Baker RO, Bray M, Herrera R, Huggins JW. Potential Antiviral Therapeutics for Smallpox, Monkeypox, and Other Orthopoxvirus Infections. Poster #96. XV International Conference on Antiviral Research, Prague, Czech Republic, March 17-21, 2002. Antiviral Res 2002; 53: A63.
375. Ballatore C, McGuigan C, De Clercq E, Balzarini J. Synthesis and evaluation of novel amidate prodrugs of PMEA and PMPA. Bioorg Medicinal Chem Letter 2001; 11: 1053-1056.
376. Chapman H, Kernan M, Prisbe E, Rohloff J, Sparacino M, Terhorst T, et al. Practical synthesis, separation, and stereochemical assignment of the PMPA pro-drug GS-7340. Nucleus Nucleot Nucleic Acids 2001; 20: 621-628.
377. Chapman H, Kernan M, Rohloff J, Sparacino M, Terhorst T. Purification of PMPA amidate prodrugs by SMB chromatography and X-ray crystallography of the diastereomerically pure GS-7340. Nucleus Nucleot Nucleic Acids 2001; 20: 1085-1090.
378. Rossi L, Dominici S, Serafini S, Casabianca A, Cerasi A, Chiarantini L, et al. Pharmacokinetic and antiretroviral activity in mice of oral [P-1,P-2-bis[2-(adenin-9-yl)ethoxymethyl]phosphonate], a prodrug of 9-(2-phosphonylmethoxyethyl)adenine. J Antimicrob Chemother 2002, 50, 365-374.
379. Sekiya K, Takashima H, Ueda N, Kamiya N, Yuasa S, Fujimura Y, et al. 2-Amino-6-arylthio-9-[2-(phosphonomethoxy) ethyl] purine bis(2,2,2-trifluoroethyl) esters as novel HBV-specific antiviral reagents. J Med Chem 2002; 45: 3138-3142.
380. Ono-Nita SK, Kato N, Shiratori Y, Carrilho FJ, Omata, M. Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus. Antimicrob. Agents Chemother 2002; 46: 2602-2605.
381. Holy A, Votruba I, Masojídková M, Andrei G, Snoeck R, Naesens L, et al. 6-2-(Phosphonomethoxy)alkoxy] pyrimidines with antiviral activity. J Med Chem 2002; 45: 1918-1929.
382. Balzarini J, Pannecouque C, De Clercq E, Aquaro S, Perno CF, Egberink H, et al. Antiretrovirus activity of a novel class of acyclic pyrimidine nucleoside phosphonates. Antimicrob Agents Chemother 2002; 46: 2185-2193.
383. Burnouf C, Pruniaux MP. Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs. Curr Pharm Design 2002; 8(14): 1255-96.
384. Lagget M, Rizzetto M. Treatment of chronic hepatitis B. Curr Pharm Design 2002; 8(11): 953-8.
385. Sardari S, Sardari D. Applications of artificial neural network in AIDS research and therapy. Curr Pharm Design 2002; 8(8): 659-70.